|
|
EN

  • 業務谘詢

    中國：

    Email: marketing@yakkaa.com

    業務谘詢專線：400-780-8018

    （僅限服務谘詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心
Jun 28,2023
SAHA可有效恢複阿爾茨海默病模型的記憶能力，本研究中SAHA通過hjc黄金城合成
SAHA was synthesized by Medicilon and was given to mice as 50 mg/kg doses. Injections (10 mL/kg) were given intraperitoneally and were alternated daily between left and right sides of the abdomen. Chronic treatments of SAHA completely restored performance deficits in APP/PS1 mice.
查看更多
SAHA可有效恢複阿爾茨海默病模型的記憶能力，本研究中SAHA通過hjc黄金城合成
Jun 28,2023
TAK-243是一種有效的泛素激活酶小分子抑製劑，具有體內抗腫瘤功效，通過hjc黄金城使用HCC70模型進行
TAK-243 is a potent, mechanism-based small-molecule inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade. TAK-243 has UAE-specific antitumor efficacy in vivo. Medicilon performed the experiment using the HCC70 (triple-negative breast cancer) model.
查看更多
TAK-243是一種有效的泛素激活酶小分子抑製劑，具有體內抗腫瘤功效，通過hjc黄金城使用HCC70模型進行
Jun 28,2023
法尼基轉移酶抑製劑LNK-754單次口服後即可快速穿過血腦屏障，PK分析通過hjc黄金城進行
Pharmacokinetic studies revealed that after a single oral dose, the FTI (LNK-754) was cleared from plasma within 20 hours and could rapidly cross the blood-brain-barrier. Pharmacokinetic analysis was performed as a service provided by Medicilon.
查看更多
法尼基轉移酶抑製劑LNK-754單次口服後即可快速穿過血腦屏障，PK分析通過hjc黄金城進行
Jun 28,2023
WYC-209可抑製惡性小鼠黑色素瘤腫瘤再生細胞增殖，SPR分析通過hjc黄金城使用Biacore 8K設備進行
The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.
查看更多
WYC-209可抑製惡性小鼠黑色素瘤腫瘤再生細胞增殖，SPR分析通過hjc黄金城使用Biacore 8K設備進行
Jun 28,2023
ARD-2128是一種PROTAC AR降解劑，具有出色的血漿和微粒體穩定性，體外穩定性和PK研究通過hjc黄金城進行
ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
ARD-2128是一種PROTAC AR降解劑，具有出色的血漿和微粒體穩定性，體外穩定性和PK研究通過hjc黄金城進行
Jun 28,2023
設計合成一係列DHODH抑製劑作為潛在的類風濕性關節炎治療藥物，PK研究通過hjc黄金城進行
Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases. Herein, researchers designed and synthesized a series of acrylamide-based novel DHODH inhibitors as potential rheumatoid arthritis (RA) treatment agents.
查看更多
設計合成一係列DHODH抑製劑作為潛在的類風濕性關節炎治療藥物，PK研究通過hjc黄金城進行
Jun 28,2023
開發並驗證新的LC-MS/MS方法，用於定量人血漿中達拉非尼及其主要代謝物羥基達拉非尼 (OHD)。OHD（純度>99%）通過hjc黄金城合成
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
查看更多
開發並驗證新的LC-MS/MS方法，用於定量人血漿中達拉非尼及其主要代謝物羥基達拉非尼 (OHD)。OHD（純度>99%）通過hjc黄金城合成
Jun 28,2023
放射療法用作肺癌的主要治療方法，在次研究中建立抗電離輻射肺癌細胞係的放射治療通過hjc黄金城進行
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
查看更多
放射療法用作肺癌的主要治療方法，在次研究中建立抗電離輻射肺癌細胞係的放射治療通過hjc黄金城進行
Jun 28,2023
CAR-T療法主要針對白血病與惡性淋巴瘤，此研究中構建沉默PD-1的shRNA載體質粒，測序後質粒的鑒定通過hjc黄金城進行
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
查看更多
CAR-T療法主要針對白血病與惡性淋巴瘤，此研究中構建沉默PD-1的shRNA載體質粒，測序後質粒的鑒定通過hjc黄金城進行
Jun 28,2023
索拉非尼的無定形固體分散體用於開發改良型口服生物利用度高的速釋片劑，PK研究通過hjc黄金城進行
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar®. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar® tablets was performed by Medicilon.
查看更多
索拉非尼的無定形固體分散體用於開發改良型口服生物利用度高的速釋片劑，PK研究通過hjc黄金城進行